China VBP Program: Redefining Medtech Go-To-Market Models

As China's tech sector faced sweeping regulatory disruptions that wiped out valuations overnight, its medtech industry began experiencing equally profound policy shifts. The China VBP Program, initially piloted for pharmaceuticals and later extended to medical devices, compels manufacturers to compete on the lowest price for entire market volumes. For more info: https://www.zs.com/insights/me....dtech-volume-based-p

Pharmaceutical Supply Chain Strategy in a Tariff-Driven Era

The pharmaceutical supply chain strategy has fundamentally shifted as trade tariffs, pricing mandates, and global policy disruptions expose deep vulnerabilities across the value chain. Rising API costs, drug shortages, and regulatory unpredictability are forcing companies to rethink sourcing, manufacturing, and risk frameworks. For more info: https://www.zs.com/insights/us....-pharma-policy-strat

Precision Marketing for Health Systems & Healthcare Personalization

This is what patients are accustomed to in their daily lives, but health systems often fail to deliver. As consumer expectations rise, Healthcare patient engagement must evolve beyond generic, one-size-fits-all campaigns. For more info: https://www.zs.com/insights/pr....ecision-marketing-fo

Patient Centricity in Pharma & Medical Affairs

Growing consumerism. Regulatory shifts. Recognition of diverse patient needs. Advances in data and analytics. These forces drive patient centricity in pharma. In medical affairs, true patient centricity medical affairs means moving beyond traditional HCP engagement to capture real-world patient experiences. For more info: https://www.zs.com/insights/pa....tient-centricity-med

Bio pharma R&D category & biotech commercialization strategy

For bio pharma r&d category strategy, shifting from science‑first to patients‑first is crucial. Data challenges assumptions (e.g., redefining target physicians). Market access is non‑negotiable; without reimbursement readiness, prescriptions fail. For more info: https://www.zs.com/insights/bi....opharma-commercializ